Avapritinib continues to demonstrate durable symptom control with a well-tolerated safety profile: Long-term outcomes from PIONEER

Journal of Allergy and Clinical Immunology 2026

View at publisher
Authors: Cem Akin, Tsewang Tashi, Hanneke Oude Elberink, Jens Panse, Deepti H. Radia, Frank Siebenhaar, Cristina Bulai Livideanu, Karin Hartmann, Sigurd Broesby‐Olsen, Tracy I. George, Vito Sabato, Paul van Daele
+24 more Sonia Cerquozzi, Ingunn Dybedal, Joseph Gerard Jurcic, Stéphane Barète, Andreas Reiter, Thanai Pongdee, Ruchi Desai, Philippe Schafhausen, Celalettin Üstün, Prithviraj Bose, Peter Vadas, Massimo Triggiani, Patrizia Bonadonna, Daniel J. DeAngelo, Lindsay A. M. Rein, Pankit J. Vachhani, Ilda Bidollari, Hui-Min Lin, Janet Hong, Benjamin Lampson, Ashley Doyle, Iván Álvarez‐Twöse, Jason R. Gotlib, Mariana Castells
DOI: 10.1016/j.jaci.2025.12.515
Cited by: 0

Fields of Study & Subjects

Mast cells and histamine Myeloproliferative Neoplasms: Diagnosis and Treatment Asthma and respiratory diseases

Publication details

Journal / source
Journal of Allergy and Clinical Immunology
Volume
157
Issue
2
Pages
AB171–AB171
Publication date
1 February 2026
Language
EN